ABVC BioPharma, Inc..
ABVC.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapeutic solutions to address unmet medical needs. The company's pipeline includes drug candidates targeting multiple indications, including oncology, and other therapeutic a...Show More
Better Health for All
-10
ABVC BioPharma's core business is developing therapeutic solutions, including safe and natural drugs for severe illnesses in ophthalmology, CNS, and oncology/hematology, with an active pipeline of six drugs and one medical device.
1
There is no evidence of revenue from products with significant negative health impacts. The company is developing ABV-1504 for Major Depressive Disorder (MDD) and conducting a clinical study for depression in cancer patients, directly addressing mental health needs.
2
ABV-1504/PDC1421 is specifically designed and has shown no signs of drug addiction in Phase II studies, aiming to be a non-addictive treatment for depression.
3
The company targets severe illnesses impacting millions worldwide, including MDD affecting over 280 million people and depression in cancer patients (40% of women with breast cancer report mild depression).
4
ABVC identifies and commercializes new drugs and medical devices developed at world-class research institutions, leveraging partnerships and in-licensed technology to advance its portfolio into clinical trials.
5
ABVC intends to invest up to $20 million in AiBtl over time and has received cumulative licensing revenue of $946,000.
6
The company conducts proof-of-concept trials through Phase II and intends to conduct pivotal Phase III clinical trials for Vitargus® and ABV-1504.
7
However, the company holds patents for ABV-1504 in the U.S., Australia, Japan, and Taiwan, valid through 2040 or 2041, with no evidence of flexibility or access programs for these patents.
8
Fair Money & Economic Opportunity
0
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on drug development and manufacturing.
1
The provided articles detail the company's investments in pharmaceutical facilities, licensing agreements, and financial performance (revenue, expenses, net loss). There is no evidence to suggest that ABVC BioPharma, Inc. operates as a financial institution or offers any lending, deposit, or other financial services to consumers. Therefore, all KPIs related to fair money and economic opportunity are scored as 'Not applicable' or 'No financial products offered' as the company's core business lies outside the scope of financial services.
Fair Pay & Worker Respect
0
No specific, concrete data points were found in the provided articles to assess ABVC.US against any of the KPIs for Fair Pay & Worker Respect. While CEO compensation was mentioned, median employee compensation was not, preventing the calculation of the CEO to median pay ratio.
1
No other relevant data for living wage, collective bargaining, safety incidents, pay equity, worker engagement, turnover, labor violations, insecure contracts, or health insurance coverage was provided.
Fair Trade & Ethical Sourcing
0
No specific, concrete data points for ABVC.US regarding fair trade certifications, audit frequency, forced or child labor incidents, supply chain traceability, remediation speed, ethical clause coverage in contracts, materials risk index, or supplier diversity spend were found in the provided articles.
1
The articles discuss general industry practices and initiatives but do not offer company-specific metrics for ABVC.US.
2
Honest & Fair Business
-20
The company noted a restatement of its 2023 financial statements, citing errors in share-based payments, interest expense recognition, and non-controlling interest.
1
Kind to Animals
0
The provided articles indicate that ABVC BioPharma Inc. utilizes animal testing in its drug development process. Specifically, drugs considered by ABVC have completed pre-clinical and disease animal model studies.
1
The company explicitly states on its website that it uses animals for pre-clinical, disease animal model, and Phase I safety studies.
2
However, the articles do not provide any quantitative data on the number of animals used, details about the company's animal testing policy, or any information regarding investment in animal-free alternatives, certifications, or other animal welfare practices.
No War, No Weapons
0
The provided articles focus on ABVC BioPharma's core business in biopharmaceuticals, including drug development and market projections for herbal medicine.
1
One article discusses a new regulatory rule from the Bureau of Industry and Security (BIS) regarding export controls on certain biotechnology products with potential dual-use for military applications.
2
However, neither article provides any specific information or data regarding ABVC BioPharma's direct involvement in arms manufacturing, military contracts, dual-use technology development by the company, sales to embargoed regimes, peacebuilding investments, or any other metrics relevant to the 'No War, No Weapons' ethical value. Consequently, no KPIs can be scored based on the evidence provided.
Planet-Friendly Business
0
The provided articles focus exclusively on ABVC BioPharma's financial performance, investment in US operations, and manufacturing expansion plans. There is no specific, concrete data available regarding any of the environmental metrics relevant to the 'Planet-Friendly Business' value, such as greenhouse gas emissions, renewable energy use, water consumption, waste diversion, or climate-related policies and initiatives.
1
Therefore, no KPIs can be scored based on the provided evidence.
Respect for Cultures & Communities
0
No specific, concrete data points were found in the provided articles regarding ABVC.US's performance on any of the KPIs related to Respect for Cultures & Communities. The articles discuss the company's research into traditional medicine and a share-for-land agreement for agricultural land, but do not provide information on community engagement, cultural impact assessments, partnerships, local employment, grievance mechanisms, or other relevant metrics.
1
Safe & Smart Tech
0
No specific, concrete data points were found in the provided articles regarding ABVC.US's performance across any of the Safe & Smart Tech KPIs, including data breach severity, AI ethics governance, cybersecurity investment, privacy certifications, security training effectiveness, encryption implementation, AI audit practices, algorithmic transparency, unauthorized data use, user data control, authentication security, vulnerability management, bug bounty effectiveness, privacy by design, security testing coverage, data minimization, regulatory compliance, algorithmic harm remediation, or digital rights advocacy.
Zero Waste & Sustainable Products
0
The provided articles, which primarily detail financial results, patent approvals, clinical trials, and licensing agreements, do not contain any specific, concrete data points or facts related to waste management, product recyclability, packaging sustainability, or any other metrics under the 'Zero Waste & Sustainable Products' ethical value. Both Article 0 and Article 1 explicitly state a lack of information regarding these metrics.
1
Article 2 is a search results page and provides no relevant content.
2